SIU Academy presents a new series of meetings called Bench to Bedside (B2B)

The first B2B—Prostate Cancer meeting will take place on September 03, 2016, in close collaboration with the Istanbul Medipol University.

A world renowned faculty lead by Prof. Jean de la Rosette and Prof. Sabahattin Aydin, will gather for one day to explore a wide variety of topics that range from prostate cancer stem cells to molecular imaging, engineering, and clinical reflection of rapid advancements in research.

Advances in genomic, proteomic and imaging technologies have led to an expansion of our understanding of cancer in general. The identification of new molecular targets has paved the way for targeted therapy, potentially increasing anti-tumour efficacy while minimizing the toxicity to the patient.1

Translational research has flourished in recent years in response to the need for transferring laboratory breakthroughs (from the bench) to the patient care setting (at the bedside) as quickly as possible; accelerating the process of translating research discoveries into new clinical treatments, practices and procedures. Thus, a multi-faceted collaboration among researchers, clinicians, and the industry is fundamental in clinical studies in order to translate laboratory findings into clinically applicable therapeutics.

The webcasts of the first B2B meeting will be available on SIU Academy after the event.